Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBITDA: 2020-2025

Historic EBITDA for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to -$12.3 million.

  • Tarsus Pharmaceuticals' EBITDA rose 46.13% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 39.39%. This contributed to the annual value of -$115.4 million for FY2024, which is 15.06% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its EBITDA stood at -$12.3 million for Q3 2025, which was up 39.49% from -$20.4 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' EBITDA's 5-year high stood at $10.4 million during Q1 2021, with a 5-year trough of -$41.9 million in Q4 2023.
  • Over the past 3 years, Tarsus Pharmaceuticals' median EBITDA value was -$25.2 million (recorded in 2025), while the average stood at -$28.1 million.
  • In the last 5 years, Tarsus Pharmaceuticals' EBITDA spiked by 630.20% in 2021 and then crashed by 446.35% in 2023.
  • Tarsus Pharmaceuticals' EBITDA (Quarterly) stood at -$14.9 million in 2021, then increased by 8.00% to -$13.7 million in 2022, then tumbled by 206.64% to -$41.9 million in 2023, then skyrocketed by 44.43% to -$23.3 million in 2024, then skyrocketed by 46.13% to -$12.3 million in 2025.
  • Its EBITDA was -$12.3 million in Q3 2025, compared to -$20.4 million in Q2 2025 and -$25.2 million in Q1 2025.